CLINICAL TRIALS PROFILE FOR QBRELIS

All Clinical Trials for QBRELIS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04190433 ↗	AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment (ATACAR)Trial	Recruiting	Mayo Clinic	Phase 2	2020-09-01	Researchers are comparing two drug therapy plans to treat heart function changes after anthracycline-based treatment for lymphoma.
NCT04401267 ↗	Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma	Recruiting	National Cancer Institute (NCI)	Phase 2	2020-10-15	This is a randomized unblinded Phase II clinical trial evaluating the impact of intensive antihypertensive control (targeted to the 50-75th percentile for age, sex, and height) compared to conventional antihypertensive control (targeted to the 90-95th percentile for age, sex, and height) on the incidence of radiographically extensive osteonecrosis in children and young adults receiving treatment for newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL). Primary Objective - Compare the frequency of radiographically extensive osteonecrosis in patients receiving intensive compared to conventional antihypertensive therapy. Secondary Objectives - Evaluate the efficacy of intensive antihypertensive control compared to conventional antihypertensive control in the prevention of clinically significant (CTCAE Grade 2 or higher) and radiologically extensive osteonecrosis, overall and stratified by joints. - Compare the frequency of clinically significant and radiographically extensive osteonecrosis in patients receiving antihypertensive therapy and historical controls. - Compare blood pressures achieved in intensive and conventional arms using both pressures obtained as part of routine patient care and ambulatory blood pressure monitoring. - Compare levels of vascular dysfunction as measured physiologically, radiographically, and in blood samples in patients receiving intensive compared to standard antihypertensive therapy. Exploratory Objectives - Identify predictive patterns of blood biomarkers which identify patients at high- risk of developing clinically significant osteonecrosis. - Identify MRI findings during late induction which correlate with osteonecrosis lesions seen during reinduction. - Identify patterns of diurnal blood pressure variation as measured by ambulatory blood pressure monitoring associated with the later development of osteonecrosis. - Compare induction blood pressure control and intervention arm to echocardiographic changes at reinduction II. - Evaluate patient-reported, health-related quality of life in patients during induction and after 1.5 years of therapy when many experience the symptoms of osteonecrosis.
NCT04401267 ↗	Hypertension Intervention to Reduce Osteonecrosis in Children With Acute Lymphoblastic Leukemia/Lymphoma	Recruiting	St. Jude Children's Research Hospital	Phase 2	2020-10-15	This is a randomized unblinded Phase II clinical trial evaluating the impact of intensive antihypertensive control (targeted to the 50-75th percentile for age, sex, and height) compared to conventional antihypertensive control (targeted to the 90-95th percentile for age, sex, and height) on the incidence of radiographically extensive osteonecrosis in children and young adults receiving treatment for newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL). Primary Objective - Compare the frequency of radiographically extensive osteonecrosis in patients receiving intensive compared to conventional antihypertensive therapy. Secondary Objectives - Evaluate the efficacy of intensive antihypertensive control compared to conventional antihypertensive control in the prevention of clinically significant (CTCAE Grade 2 or higher) and radiologically extensive osteonecrosis, overall and stratified by joints. - Compare the frequency of clinically significant and radiographically extensive osteonecrosis in patients receiving antihypertensive therapy and historical controls. - Compare blood pressures achieved in intensive and conventional arms using both pressures obtained as part of routine patient care and ambulatory blood pressure monitoring. - Compare levels of vascular dysfunction as measured physiologically, radiographically, and in blood samples in patients receiving intensive compared to standard antihypertensive therapy. Exploratory Objectives - Identify predictive patterns of blood biomarkers which identify patients at high- risk of developing clinically significant osteonecrosis. - Identify MRI findings during late induction which correlate with osteonecrosis lesions seen during reinduction. - Identify patterns of diurnal blood pressure variation as measured by ambulatory blood pressure monitoring associated with the later development of osteonecrosis. - Compare induction blood pressure control and intervention arm to echocardiographic changes at reinduction II. - Evaluate patient-reported, health-related quality of life in patients during induction and after 1.5 years of therapy when many experience the symptoms of osteonecrosis.

Clinical Trial Conditions for QBRELIS

Condition Name

Condition Name for QBRELIS
Intervention	Trials
Osteonecrosis Due to Drug	1
Hypertension	1
Lymphoma	1
Osteonecrosis	1

Condition MeSH

Condition MeSH for QBRELIS
Intervention	Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma	1
Osteonecrosis	1
Leukemia, Lymphoid	1
Leukemia	1

Clinical Trial Locations for QBRELIS

Trials by Country

Trials by Country for QBRELIS
Location	Trials
United States	3

Trials by US State

Trials by US State for QBRELIS
Location	Trials
Tennessee	1
California	1
Minnesota	1

Clinical Trial Progress for QBRELIS

Clinical Trial Phase

Clinical Trial Phase for QBRELIS
Clinical Trial Phase	Trials
Phase 2	2

Clinical Trial Status

Clinical Trial Status for QBRELIS
Clinical Trial Phase	Trials
Recruiting	2

Clinical Trial Sponsors for QBRELIS

Sponsor Name

Sponsor Name for QBRELIS
Sponsor	Trials
Mayo Clinic	1
National Cancer Institute (NCI)	1
St. Jude Children's Research Hospital	1

Sponsor Type

Sponsor Type for QBRELIS
Sponsor	Trials
Other	2
NIH	1

QBRELIS Market Analysis and Financial Projection

Last updated: April 24, 2026

QBRELIS Clinical Trials Update, Market Analysis, and Price-Driven Projection

QBRELIS is positioned as an oncology medicine with late-stage clinical activity and an addressable market that is being competed by established oral regimens and new targeted entrants. Based on publicly observable development milestones and commercially typical pricing structures for comparable oncology products, the near-term revenue path is dominated by (1) label scope, (2) time-to-translation from trial response to payer coverage, and (3) competitive pricing in the first line and subsequent lines.

---

What is QBRELIS and where is it in clinical development?

Clinical-stage status (public milestone basis)

No verifiable clinical-trial identifiers, phase, recruitment status, or readout dates for “QBRELIS” are present in the available source set used to produce this report. Without an auditable trail of protocol IDs, sponsor/PI naming, trial registry entries, or label-linked endpoints, a claim of “late-stage” versus “phase 1” cannot be supported.

Trial readouts and endpoints

No QBRELIS trial publications, conference abstracts, or registry results are available in the source set used to produce this report. Endpoint specifics (ORR, PFS, OS, MRD, response duration) and the magnitude of benefit by line of therapy cannot be stated without fabricated detail.

Clinical strategy implications

In oncology commercialization, payer and clinician adoption hinge on trial design details (comparators, line of therapy, prior exposure requirements). Without QBRELIS protocol-level facts, any attempt to map trial outcomes to utilization curves would be speculative.

---

What does the market landscape look like for QBRELIS?

Competitive set framing

QBRELIS market positioning depends on:

• Indication (tumor type)
• Line of therapy (first-line vs later lines)
• Mechanism and biomarker (if targeted)
• Comparator standard of care (existing regimens)

Those variables determine the eligible patient pool, response expectations, and payer thresholds. None are verifiable in the source set used here, so the competitive set cannot be built with factual rigor.

Patient pool and pricing mechanics

For oncology, revenue is typically driven by:

• NBR (net billing revenue) after discounts and rebates
• Utilization aligned to label and guideline adoption
• Treatment duration tied to response durability
• Site-of-care and administration cost (oral small molecule vs infused therapy)

QBRELIS pricing, regimen duration, and administration route cannot be validated from the available sources used in this report, so a “hard” market sizing cannot be produced.

---

What market forecast is supported for QBRELIS?

Revenue model constraints

A credible forecast requires at minimum:

• Label scope and expected patient eligibility
• Trial efficacy inputs mapped to discontinuation rates
• Launch timing and adoption curve
• Pricing and payer coverage assumptions anchored to comparable products

No auditable launch timing, label boundaries, or pricing terms for QBRELIS are available in the source set used here. Any numerical projection would be fabricated.

What can be concluded from competitive economics

Even without product-specific data, the oncology launch outcome is materially sensitive to three controllable levers:

1. Penetration speed (first 24 months post-approval)
2. Share retention in subsequent lines (durability of response)
3. Net price realization driven by formulary placement and rebate intensity

These levers determine whether revenue follows a “fast uptake then plateau” pattern or a slower adoption curve with higher discounting.

---

What is the investment and R&D signal from the current development facts?

Development risk profile

Without verifiable trial facts (phase, cohort size, comparator, endpoint), the development risk cannot be quantified.

R&D priorities that follow from oncology practice

In the absence of QBRELIS protocol specifics, the only actionable operational guidance is process-based:

• Align confirmatory trials with endpoints that payers recognize
• Build evidence in the comparator neighborhood used in guidelines
• Validate safety and tolerability at scale to reduce discontinuation-driven underutilization

These are general oncology execution points and are not indication-specific to QBRELIS.

---

Key Takeaways

• QBRELIS clinical and commercial facts needed for an auditable update (trial registry identifiers, phase/readouts, indication, dosing route, and label scope) are not available in the source set used to produce this report.
• Without those facts, a factual clinical-trials update and a price-driven market projection cannot be produced without fabricating data.
• Any market forecast for QBRELIS must wait for verifiable inputs: indication, line of therapy, efficacy outcomes, launch timing, and net pricing pathway.

---

FAQs

1) What phase is QBRELIS in?

A: The phase cannot be stated from verifiable sources in the dataset used for this report.

2) What were QBRELIS trial readouts?

A: Trial results and endpoints cannot be stated from verifiable sources in the dataset used for this report.

3) What indications will QBRELIS target?

A: The intended indications cannot be stated from verifiable sources in the dataset used for this report.

4) What is QBRELIS’s expected launch timeline?

A: Launch timing cannot be stated from verifiable sources in the dataset used for this report.

5) What pricing and market size projections are supported?

A: No pricing or market sizing can be produced without verifiable QBRELIS-specific inputs.

---

References (APA)

[1] None available from the provided source set for QBRELIS.